Terms: = Ovarian cancer AND CHD4, Mi2-BETA, 1108, ENSG00000111642, Mi-2b, DKFZp686E06161, Q14839 AND Treatment
5 results:
1. The epigenetic factor chd4 contributes to metastasis by regulating the EZH2/β-catenin axis and acts as a therapeutic target in ovarian cancer.
Wang J; Zhong F; Li J; Yue H; Li W; Lu X
J Transl Med; 2023 Jan; 21(1):38. PubMed ID: 36681835
[TBL] [Abstract] [Full Text] [Related]
2. Levonorgestrel-releasing intrauterine system for endometrial hyperplasia.
Mittermeier T; Farrant C; Wise MR
Cochrane Database Syst Rev; 2020 Sep; 9(9):CD012658. PubMed ID: 32909630
[TBL] [Abstract] [Full Text] [Related]
3. Surgical wait time: A new health indicator in women with endometrial cancer.
Strohl AE; Feinglass JM; Shahabi S; Simon MA
Gynecol Oncol; 2016 Jun; 141(3):511-515. PubMed ID: 27103178
[TBL] [Abstract] [Full Text] [Related]
4. High Expression of miR-532-5p, a Tumor Suppressor, Leads to Better Prognosis in ovarian cancer Both In Vivo and In Vitro.
Wang F; Chang JT; Kao CJ; Huang RS
Mol Cancer Ther; 2016 May; 15(5):1123-31. PubMed ID: 26873729
[TBL] [Abstract] [Full Text] [Related]
5. A systematic comparison of the anti-tumoural activity and toxicity of the three Adv-TKs.
Gao Q; Chen C; Ji T; Wu P; Han Z; Fang H; Li F; Liu Y; Hu W; Gong D; Zhang Z; Wang S; Zhou J; Ma D
PLoS One; 2014; 9(4):e94050. PubMed ID: 24722669
[TBL] [Abstract] [Full Text] [Related]
